Cargando…

A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression

BACKGROUND: Local progression-free survival (LPFS = stable or improved motor function/resolution of paraplegia during RT without in-field recurrence following RT) is important when treating metastatic spinal cord compression (MSCC). An instrument to estimate LPFS was created to identify patients app...

Descripción completa

Detalles Bibliográficos
Autores principales: Rades, Dirk, Conde-Moreno, Antonio J., Cacicedo, Jon, Veninga, Theo, Segedin, Barbara, Stanic, Karmen, Schild, Steven E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311053/
https://www.ncbi.nlm.nih.gov/pubmed/30594231
http://dx.doi.org/10.1186/s13014-018-1203-y
_version_ 1783383544607801344
author Rades, Dirk
Conde-Moreno, Antonio J.
Cacicedo, Jon
Veninga, Theo
Segedin, Barbara
Stanic, Karmen
Schild, Steven E.
author_facet Rades, Dirk
Conde-Moreno, Antonio J.
Cacicedo, Jon
Veninga, Theo
Segedin, Barbara
Stanic, Karmen
Schild, Steven E.
author_sort Rades, Dirk
collection PubMed
description BACKGROUND: Local progression-free survival (LPFS = stable or improved motor function/resolution of paraplegia during RT without in-field recurrence following RT) is important when treating metastatic spinal cord compression (MSCC). An instrument to estimate LPFS was created to identify patients appropriately treated with short-course RT instead of longer-course RT plus/minus decompressive surgery. METHODS: In 686 patients treated with 20 Gy in 5 fractions alone, ten characteristics were retrospectively analyzed for LPFS including age, interval between tumor diagnosis and RT of MSCC, visceral metastases, other bone metastases, primary tumor type, gender, time developing motor deficits, pre-RT gait function, number of vertebrae affected by MSCC, and performance score. Characteristics significantly (p < 0.05) associated with LPFS on multivariate analyses were incorporated in the scoring system. Six-month LPFS rates for significant characteristics were divided by 10, and corresponding points were added. RESULTS: On multivariate analyses, visceral metastases (p < 0.001), tumor type (p = 0.009), time developing motor deficits (p < 0.001) and performance score (p = 0.009) were associated with LPFS and used for the scoring system. Scores for patients ranged between 24 and 35 points. Three groups were designed: 24–28 (A), 29–31 (B) and 32–35 (C) points. Six-month LPFS rates were 46, 69 and 92%, 12-month LPFS rates 46, 63 and 83%. Median survival times were 2 months (61% died within 2 months), 4 months and ≥ 11 months (median not reached). CONCLUSIONS: Most group A patients appeared sub-optimally treated with 20 Gy in 5 fractions. Patients with survival prognoses ≤2 months may be considered for best supportive care or single-fraction RT, those with prognoses ≥3 months for longer-course RT plus/minus upfront decompressive surgery. Many group B and most group C patients achieved long-time LPFS and appeared sufficiently treated with 20 Gy in 5 fractions. However, based on previous data, long-term survivors may benefit from longer-course RT.
format Online
Article
Text
id pubmed-6311053
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63110532019-01-07 A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression Rades, Dirk Conde-Moreno, Antonio J. Cacicedo, Jon Veninga, Theo Segedin, Barbara Stanic, Karmen Schild, Steven E. Radiat Oncol Research BACKGROUND: Local progression-free survival (LPFS = stable or improved motor function/resolution of paraplegia during RT without in-field recurrence following RT) is important when treating metastatic spinal cord compression (MSCC). An instrument to estimate LPFS was created to identify patients appropriately treated with short-course RT instead of longer-course RT plus/minus decompressive surgery. METHODS: In 686 patients treated with 20 Gy in 5 fractions alone, ten characteristics were retrospectively analyzed for LPFS including age, interval between tumor diagnosis and RT of MSCC, visceral metastases, other bone metastases, primary tumor type, gender, time developing motor deficits, pre-RT gait function, number of vertebrae affected by MSCC, and performance score. Characteristics significantly (p < 0.05) associated with LPFS on multivariate analyses were incorporated in the scoring system. Six-month LPFS rates for significant characteristics were divided by 10, and corresponding points were added. RESULTS: On multivariate analyses, visceral metastases (p < 0.001), tumor type (p = 0.009), time developing motor deficits (p < 0.001) and performance score (p = 0.009) were associated with LPFS and used for the scoring system. Scores for patients ranged between 24 and 35 points. Three groups were designed: 24–28 (A), 29–31 (B) and 32–35 (C) points. Six-month LPFS rates were 46, 69 and 92%, 12-month LPFS rates 46, 63 and 83%. Median survival times were 2 months (61% died within 2 months), 4 months and ≥ 11 months (median not reached). CONCLUSIONS: Most group A patients appeared sub-optimally treated with 20 Gy in 5 fractions. Patients with survival prognoses ≤2 months may be considered for best supportive care or single-fraction RT, those with prognoses ≥3 months for longer-course RT plus/minus upfront decompressive surgery. Many group B and most group C patients achieved long-time LPFS and appeared sufficiently treated with 20 Gy in 5 fractions. However, based on previous data, long-term survivors may benefit from longer-course RT. BioMed Central 2018-12-29 /pmc/articles/PMC6311053/ /pubmed/30594231 http://dx.doi.org/10.1186/s13014-018-1203-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Rades, Dirk
Conde-Moreno, Antonio J.
Cacicedo, Jon
Veninga, Theo
Segedin, Barbara
Stanic, Karmen
Schild, Steven E.
A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
title A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
title_full A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
title_fullStr A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
title_full_unstemmed A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
title_short A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
title_sort scoring system to predict local progression-free survival in patients irradiated with 20 gy in 5 fractions for malignant spinal cord compression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311053/
https://www.ncbi.nlm.nih.gov/pubmed/30594231
http://dx.doi.org/10.1186/s13014-018-1203-y
work_keys_str_mv AT radesdirk ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT condemorenoantonioj ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT cacicedojon ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT veningatheo ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT segedinbarbara ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT stanickarmen ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT schildstevene ascoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT radesdirk scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT condemorenoantonioj scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT cacicedojon scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT veningatheo scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT segedinbarbara scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT stanickarmen scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression
AT schildstevene scoringsystemtopredictlocalprogressionfreesurvivalinpatientsirradiatedwith20gyin5fractionsformalignantspinalcordcompression